Melanotan I 10mg

Melanotan I, also known as Afamelanotide or [Nle4,D-Phe7]-alpha-MSH, is a synthetic linear analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It is a 13-amino-acid peptide that was developed at the University of Arizona as a more potent and metabolically stable version of the native alpha-MSH molecule.

Melanotan I is a non-selective melanocortin receptor agonist with primary activity at the MC1R (melanocortin 1 receptor), which is the receptor subtype principally responsible for melanogenesis, the production of melanin pigment in melanocytes.

Preclinical and clinical research has investigated Melanotan I in models of melanogenesis, UV-associated DNA damage protection, and erythropoietic protoporphyria (EPP). Afamelanotide received regulatory approval in the European Union (2014) and Australia (2020) under the brand name Scenesse for the prevention of phototoxicity in adult patients with EPP.

Research interest extends beyond pigmentation to include studies of melanocortin receptor binding kinetics, photoprotection mechanisms, and structure-activity relationships within the melanocortin peptide family.

For In-Vitro Research Use Only. Not for human consumption, veterinary use, or clinical application. No dosing guidance is provided or implied.